n.a. (QLTI)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
'Cash Is King' Stocks

'Cash Is King' Stocks

With credit hard to come by, companies with cash on hand are worth a second look.

Health Winners & Losers: Amylin

Health Winners & Losers: Amylin

Amylin falls on a downgrade.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Biotech indices are sinking, but Cardiome and QLT surge.

Wednesday's Winners and Losers: Linktone

The Shanghai-based telecom media provider soars 32% on an investment by PT Media Nusantara Citra.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

QLT climbs on news it's looking into 'strategic alternatives.'

Wednesday's Small-Cap Winners & Losers

Wednesday's Small-Cap Winners & Losers

Linktone climbs on an investment by PT Media Nusantara Citra.

Lucentis Cleared in Europe

Lucentis Cleared in Europe

Novartis will sell the drug.

QLT Hit by Sales Drop

QLT Hit by Sales Drop

Visudyne sales are hit by the release of Lucentis.

QLT to Buy Back Shares

QLT to Buy Back Shares

The biopharmaceutical company plans to pay $104 million under the Dutch auction tender offer.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

J&J is higher a day before its earnings report.

Genentech's Lucentis Cleared

Genentech's Lucentis Cleared

The drug treats an eye disease that can lead to blindness.

Today's Health Winners and Losers

Today's Health Winners and Losers

Martek shares jump on a new supply deal with Mead Johnson.

Today's Health Winners and Losers

Today's Health Winners and Losers

Kensey Nash advances after its third-quarter earnings beat forecasts.

Profits Surge for Novartis

First-quarter sales rise 13%.

Trade Like Seth Klarman

This value maestro has an eclectic portfolio that bears close inspection.

Weekend Reading: Economic Smorgasbord

It will be a busy week, with a slew of data on tap and Ben Bernanke's first FOMC meeting as Fed chairman.

How to Find Crossover Hits

Don't buy a stock just because it crosses above its 200-day moving average.

Four Stocks for a Bear Market

Four Stocks for a Bear Market

Screening by enterprise value and EBITDA is a good way to find stocks trading at a discount.

Four Stocks for a Bear Market

Screening by enterprise value and EBITDA is a good way to find stocks trading at a discount.

Lucentis Gets Priority Review

Lucentis Gets Priority Review

The Genentech drug has performed well in trials.

OccuLogix Crushed After Rheo Trial

OccuLogix Crushed After Rheo Trial

The company's shares plunge nearly 70% after clinical data disappoint.

All Eyes on Genentech

All Eyes on Genentech

The company files its application for Lucentis with the FDA.

No Easy Encore for Genentech

No Easy Encore for Genentech

The biotech's biggest enemy in 2006 might be its own past successes.

Health Stocks in Motion

Health Stocks in Motion

Neurogen gains after its insomnia drug performs well in a Phase I trial.

QLT Eyes Big Job Cuts

QLT Eyes Big Job Cuts

The company may terminate up to 46% of its workers and it also lowers its forecast for Visudyne sales.

Health Stocks in Motion

Health Stocks in Motion

Arimoclomol gets the fast track.

QLT Falls on Eye Treatment Study

QLT Falls on Eye Treatment Study

Its Visudyne fails to meet two-year goals in a subgroup of macular degeneration patients.

Alcon Gets Conditional OK for Eye Cure

Alcon Gets Conditional OK for Eye Cure

The company, with Retaane, is bidding to join a field including Eyetech, Genentech and QLT.

Eyetech Fails DNA Test

Eyetech Fails DNA Test

The maker of Macugen sees its market cap plunge 45% as a possible competitor from Genentech comes calling.

Genentech Data Send Eyetech Reeling

Genentech Data Send Eyetech Reeling

The company's shares are down 40% in premarket trading Tuesday.